There´s a lot of stuff going on with this pruduct on the clinic this days, even a combo trial with radiation therapy and 2DG in the University of IOWA, and I guess you know who will win when studies are done in a few years, the CANCER PATIENT and THLD.
2-DG-based chemotherapy/radiotherapy will result in enhanced therapeutic efficacy.
I should expect the company to ask for a Food and Drug Administration approval in late 2011, after p2 & p3 trials are approved in combo with other many different drugs and radiation therapy, and of course in association with a partner. This product should be the first THLD & partner drug on the market, it has achieved decades of studies with good results on safety and efficacy. By then TH-302 should be on P3 and glufosfamide forgotten (renal issues?). By then I´ll be dead and PPS should be round the $30s. Good luck!